Background: Seborrheic dermatitis is considered to be a Malassezia-driven disease. Little objective information is available so far from biometrological quantitative assessments of this skin condition. Pramiconazole is a novel triazole with potent in vitro antifungal activity, especially against Malassezia spp. Objective: To study the sequential effects of pramiconazole on Malassezia, inflammation and epidermal changes. Method: This study was performed in 2 groups of subjects suffering from seborrheic dermatitis. The first group (n = 17) remained untreated and was used as control. Clinical, mycological and biometrological assessments were performed at inclusion and during the following 2 weeks. The second group of subjects (n = 10) received a single 200-mg oral dose of pramiconazole at inclusion. Clinical, mycological and biometrological evaluations were performed before and during 1 month following the single antifungal intake. For both parts of the study, several parameters were assessed including yeast density, desquamation, erythema, itching and sebum excretion. Results: In the control group, no significant changes were observed in any of the parameters during the observation period. The findings were markedly different in the pramiconazole-treated subjects. The yeast density was significantly improved on days 3, 7 and 28. Desquamation, erythema, itching, and the global clinical evaluation as assessed by the patients and investigators became significantly improved on days 7 and 28. A trend in decrease of scaliness was noted. No effect on sebum excretion was evidenced. In conclusion, a single 200-mg dose of pramiconazole exhibitsin vivo efficacy in controlling some important clinical aspects of seborrheic dermatitis. Following a reduction in the number of yeasts on day 3, a decrease in the severity of clinical signs and symptoms occurred from day 7 onwards. Sebum excretion appeared uninvolved in the clearing process of seborrheic dermatitis. Conclusion: A single 200-mg dose of pramiconazole appears to abate seborrheic dermatitis. The density in Malassezia present on lesional skin is first decreased, followed by clearing of the clinical signs.

Keywords:
Seborrheic dermatitis, Malassezia spp. antifungal, Pramiconazole, Biometrology
1.
Shuster S: The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984;111:235–242.
2.
Hay RJ, Graham-Brown RA: Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol 1997;22:3–6.
3.
Piérard-Franchimont C, Arrese JE, Durupt G, Ries G, Cauwenbergh G, Piérard GE: Correlation between Malassezia spp. load and dandruff severity. J Mycol Med 1998;8:83–96.
4.
Faergemann J: Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75–80.
5.
Piérard-Franchimont C, Hermanns JF, Degreef H, Arrese JE, Piérard GE: From axioms to new insights into dandruff. Dermatology 2000;200:93–98.
6.
Crespo EV, Delgado FV: Malassezia species in skin diseases. Curr Opin Infect Dis 2002;15:133–142.
7.
Gupta AK, Bluhm R: Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004;18:13–16.
8.
Gupta AK, Madzia SE, Batra R: Etiology and management of seborrheic dermatitis. Dermatology 2004;208:89–93.
9.
Gupta AK, Nicol K, Batra R: Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol 2004;5:417–422.
10.
McGinley KJ, Leyden JJ, Marples RR, Kligman AM: Quantitative microbiology of the scalp in non-dandruff, dandruff and seborrhoeic dermatitis. J Invest Dermatol 1975;64:401–405.
11.
Bergbrant IM, Faergemann J: Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm Venereol 1989;69:401–405.
12.
Piérard-Franchimont C, Arrese JE, Piérard GE: Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995;4:14–19.
13.
Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G: Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001;144:549–556.
14.
McGrath J, Murphy GM: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs 1991;41:178–184.
15.
Baroni A, De Rosa R, De Rosa A, Donnarumma G, Catalanotti P: New strategies in dandruff treatment: growth control of Malasseziaovalis. Dermatology 2000;201:146–147.
16.
Piérard-Franchimont C, Piérard GE, Arrese JE, De Doncker P: Effect of ketoconazole 1 and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001;202:171–176.
17.
Piérard-Franchimont C, Piérard GE: A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology 2002;204:344–347.
18.
Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE: A multicenter randomized trial of ketocoanzole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002;15:434–441.
19.
Piérard GE: Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology 2003;206:187–188.
20.
Conti-Diaz IA, Civila E, Asconegui F: Treatment of superficial and deep-seated mycoses with oral ketoconazole. Int J Dermatol 1984;23:207–210.
21.
Ford GP, Farr PM, Ive FA, Shuster S: The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984;111:603–607.
22.
Caputo R, Barbareschi M: Itraconazole: new horizons. G Ital Dermatol Venereol 2002;137:1–7.
23.
Scapparo E, Quadri G, Virno G, Orifici C, Milani M: Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis: a multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001;144:854–857.
24.
Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, Meerpoel L, Odds F, Borgers M: The novel azole R1266838 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis. Antimicrob Agents Chemother 2004;48:3272–3278.
25.
Odds F, Ausma J, Van Gerven F, Woestenborghs F, Meerpoel L, Heeres J, Vanden Bossche A, Borgers M: In vitro and in vivo activities of a novel azole antifungal agent: R126638. Antimicrob Agents Chemother 2004;48:388–391.
26.
Baran R, Gupta AK, Piérard GE: Pharmacotherapy of onychomycosis. Exp Opin Pharmacother 2005;6:609–624.
27.
Piérard-Franchimont C, Ausma J, Wouters L, Vroome V, Vandeplassche L, Borgers M, Cauwenbergh G, Piérard GE: Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol Physiol 2006;19:49–56.
28.
Piérard GE, Piérard-Franchimont C, Marks R, Paye M, Rogiers V; the EEMCO group: EEMCO guidance for the in vivo assessment of skin greasiness. Skin Pharmacol Appl Skin Physiol 2000;13:372–389.
29.
Piérard-Franchimont C, Piérard GE: Post-menopausal aging of the sebaceous follicle: a comparison between women receiving hormone replacement therapy or not. Dermatology 2002;204:17–22.
30.
Piérard GE: EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998;10:1–11.
31.
Lévêque JL: EEMCO guidance for the assessment of skin topography. J Eur Acad Dermatol Venereol 1999;12:103–114.
32.
Piérard GE: EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: evaluation by stratum corneum strippings. Skin Res Technol 1996;2:3–11.
33.
Piérard-Franchimont C, Willemaers V, Friature AL, Piérard GE: Squamometry in seborrheic dermatitis. Int J Dermatol 1999;38:712–715.
34.
Piérard-Franchimont C, Henry F, Piérard GE: The SACD method and the XLRS squamometry tests revisited. Int J Cosmet Sci 2000;22:437–446.
35.
Naka W, Hanyaku H, Tajima S, Harada T, Nishikawa T: Applications of neutral red staining for evaluation of the viability of dermatophytes and Candida in human skin scales. J Med Vet Mycol 1994;32:31–35.
36.
Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC: In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 2000;142:758–765.
37.
Piérard GE, Arrese JE, Piérard-Franchimont C: Itraconazole corneofungimetry bioassay on Malassezia species. Mycoses 2004;47:418–421.
38.
Bergbrant IM, Faergemann J: Adherence of Malassezia furfur to human stratum corneum cells in vitro: a study of healthy individuals and patients with seborrhoeic dermatitis. Mycoses 1994;37:217–219.
39.
Piérard GE, Xhauflaire-Uhoda E, Piérard-Franchimont C: The key role of corneocytes in pityrosporoses. Dermatology 2006;212:23–26.
40.
Donnarumma G, Paoletti I, Buommino E, Orlando M, Tufano MA, Baroni A: Malassezia furfur induces the expression of β-defensin-1 in human keratinocytes in a protein kinase C-dependent manner. Arch Dermatol Res 2004;295:474–481.
41.
Rosen T, Schell BJ, Orengo I: Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997;36:788–792.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.